Iovance Biotherapeutics (IOVA) Stock Rallies on Analyst Upgrades, Amtagvi Momentum

SAN CARLOS, Calif. — Shares of **Iovance Biotherapeutics Inc.** (NASDAQ: IOVA) climbed sharply in early March 2026 trading, fueled by renewed analyst optimism and ongoing commercial progress for its flagship tumor-infiltrating lymphocyte (TIL) therapy, **Amtagvi** (lifileucel). The biotech company’s stock, which has hovered in the low single digits for much of the year, gained traction after multiple price target increases and positive commentary on its revenue trajectory.

As of March 7, 2026, IOVA closed at approximately $5.13, up from recent lows around $4.58, with intraday highs reaching $5.16 in heavy volume sessions. The stock has seen notable volatility, trading in a 52-week range from $1.64 to $5.16, reflecting broader biotech sector pressures but also bursts of enthusiasm tied to clinical and commercial milestones.

The latest catalyst came from UBS, which raised its price target on IOVA from $2 to $4, citing strong fourth-quarter revenue growth for Amtagvi despite a challenging market environment. Other firms followed suit: Baird increased its target to $4 from $3, Barclays to $11 from $10, and Citizens upgraded the stock to Outperform from Market Perform. These adjustments highlight growing confidence in Iovance’s ability to scale its pioneering TIL platform beyond advanced melanoma.

Amtagvi, the first FDA-approved TIL therapy, received accelerated approval in February 2024 for adult patients with unresectable or metastatic melanoma previously treated with other therapies. The personalized cell therapy, manufactured from a patient’s own tumor tissue, has driven rapid revenue ramp-up in its first full commercial year.

Iovance reported preliminary full-year 2025 product revenue of approximately $264 million, within its guided range of $250 million to $300 million. This marked a 61% increase from 2024’s $164.1 million, largely propelled by Amtagvi’s U.S. sales of about $220 million and global Proleukin (aldesleukin) contributions of roughly $44 million. Fourth-quarter product revenue hit $86.8 million, up about 30% sequentially, with gross margins improving to around 50% as manufacturing efficiencies took hold.

Management emphasized accelerating demand through an expanding network of authorized treatment centers (ATCs), faster production turnaround times (32 days or less), and supportive real-world data demonstrating durable responses in advanced melanoma. In a February 2026 earnings update, executives described 2026 as poised for “remarkable” revenue growth, with detailed U.S. product guidance forthcoming soon. Long-term goals include gross margins approaching 70% through full internalization of lifileucel manufacturing.

Pipeline advancements further bolster the bullish case. On February 24, 2026, Iovance announced positive early results from the first clinical trial of lifileucel in soft tissue sarcomas, specifically undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). The study showed a 50% confirmed objective response rate, prompting plans for a registrational trial. The data, presented at scientific meetings, sparked a 25%+ single-day stock surge earlier in the year.

In non-small cell lung cancer (NSCLC), lifileucel earned FDA Fast Track designation for second-line advanced non-squamous NSCLC, supported by interim data showing a 26% objective response rate and durable benefit compared to standard docetaxel. Management targets a supplemental biologics license application (sBLA) and potential accelerated approval/launch in the second half of 2027, eyeing a multibillion-dollar U.S. peak sales opportunity in lung cancer—potentially seven times larger than melanoma.

Additional trials explore frontline melanoma combinations (TILVANCE-301), second-line NSCLC (IOV-LUN-202), endometrial cancer (IOV-END-201), and next-generation engineered TIL therapies like IOV-5001, with an IND submission planned for the first half of 2026. International regulatory progress includes priority reviews in Australia and recommendations in Switzerland, with decisions expected in early 2026.

Financially, Iovance ended 2025 with about $303 million in cash, providing runway into the third quarter of 2027. Full-year costs and expenses totaled around $667 million, resulting in a net loss of $391 million, or $1.09 per share—improvements over prior periods but underscoring the cash-intensive nature of commercial-scale cell therapy.

Analysts maintain a mixed but increasingly positive consensus, with average price targets around $9–$10 implying substantial upside from current levels. High-risk elements persist: competition in solid tumors, manufacturing complexities, and the need for consistent revenue scaling amid biotech funding challenges. Yet, Iovance’s leadership in TIL therapy positions it as a potential platform player if label expansions materialize.

Upcoming investor visibility includes presentations at the TD Cowen 46th Annual Healthcare Conference on March 2 and the Barclays 28th Annual Global Healthcare Conference on March 11, where leadership will likely discuss growth drivers and 2026 guidance.

As Iovance transitions from launch-year execution to multi-indication expansion, the stock’s performance hinges on Amtagvi’s sustained momentum and pipeline catalysts. Investors watch closely for first-quarter 2026 results, expected in May, which could provide clearer visibility into the year’s trajectory.

With its innovative approach to solid tumor immunotherapy and accelerating commercial story, Iovance Biotherapeutics remains a high-conviction name in the biotech space amid 2026’s evolving oncology landscape.